San Jose, CA (PRWEB) July 23, 2014
Theravent® Advanced Nightly Snore Therapy is the first and only FDA-cleared Expiratory Positive Airway Pressure (EPAP) therapy designed to reduce or eliminate snoring. Since 2012, Theravent REGULAR strength has surpassed over 1 million quiet nights of sleep for snorers and their bed partners. This August, the company will release Theravent LITE and Theravent MAX to further its mission of reducing or eliminating snoring in America, and beyond.
Theravent was clinically tested at leading research institutions across the United States. In these studies, both the bed partners and the monitoring equipment determined that Theravent significantly reduced snoring. The results of these studies were presented at the 2010 Associated Professional Sleep Societies (APSS) conference, the prestigious medical conference sponsored by the American Academy of Sleep Medicine. The study and results were published in the journal, Sleep Diagnosis and Therapy.
“Everyone deserves a quiet night of sleep without the burden of snoring, and we will continue to do our best to help make this a reality,” said Theravent CEO, Matt Williams. “The addition of Theravent LITE and Theravent MAX enables us to provide snoring solutions for all types of primary snoring.”
Theravent LITE has half the resistance level of Theravent REGULAR. Theravent LITE was designed for light to moderate snorers, and for those that have difficulty with nasal airway resistance.
Theravent MAX has double the resistance level of Theravent REGULAR, designed to tackle heavier snoring. In clinical trials, Theravent MAX showed a 73% reduction in snoring vs. a 22% reduction by nasal strips. Additionally, 89% of bed partners reported that Theravent MAX reduced their partners' loud snoring significantly. Now, Theravent Advanced Nightly Snore Therapy offers a complete range with three products (LITE, REGULAR and MAX) to effectively and comfortably manage snoring.
To celebrate the launch of the new snoring products, http://www.Theravent.com is offering 10% off pre-orders of Theravent LITE and MAX, along with Free Shipping for the month of August.
“I’m extremely proud of all the efforts made by the Theravent team to bring these new products to market and offer new solutions for so many snorers and their bed partners,” said Williams. “Lack of sleep can cause many health problems and avoidable frustration. As a snorer myself, I fully understand the need for an affordable, comfortable and easy-to-use snoring solution that actually works.”
Matt Williams, the CEO of Theravent, is available to journalists and bloggers who submit an interview request leading up to the official launch of Theravent LITE and Theravent MAX.
About Theravent, Inc.
Theravent, Inc. is a privately held medical device company dedicated to providing noninvasive medical solutions for people with sleep disordered breathing. Based on its innovative MicroValve technology and patented designs, Theravent, Inc. has developed a unique line of clinically-proven medical devices to address the continuum of sleep disorders from severe obstructive sleep apnea (OSA) to lite, moderate and heavy snoring. Theravent, Inc.'s devices work by creating expiratory positive airway pressure (EPAP). The company markets prescription-only Provent® Sleep Apnea Therapy, a discreet, easy-to-use nasal device for the treatment of OSA, and Theravent® Advanced Nightly Snore Therapy, an over-the-counter device for the treatment of primary snoring, in the USA. Provent is also available in Australia, New Zealand, Canada, Hong Kong, Singapore and South Africa. For more information, please visit http://www.proventtherapy.com or http://www.theravent.com.